ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1532

Identifying and Assessing the Phenotypic Features of HNF1B Deletions and Duplications in UK Biobank

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Sukcharoen, Kittiya, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, United Kingdom
  • Bingham, Coralie, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, United Kingdom
  • Weedon, Michael, University of Exeter Medical School, Exeter, Devon, United Kingdom
  • Oram, Richard A., University of Exeter Medical School, Exeter, Devon, United Kingdom

Group or Team Name

  • University of Exeter
Background

Heterozygous mutations of hepatocyte nuclear factor 1β (HNF1B) are the most common known monogenic cause of developmental kidney disease. Renal cysts are the most frequently detected feature. Other features include early-onset diabetes and abnormal liver function. It is thought that duplications of HNF1B do not result in strong phenotypic features.

The true pathogenicity and penetrance of many rare putative disease-causing copy number variants (CNVs) is uncertain and may be over-estimated by clinical ascertainment.
We aimed to assess the pathogenicity and penetrance of HNF1B deletions and duplications in UK Biobank (UKBB) and to describe any associated phenotype.

Methods

We used data from 388,714 UKBB participants to assess CNVs of HNF1B in a population-based setting using SNP chip intensity data. We tested the association of these CNVs with diabetes and other clinically-relevant traits. We assessed the UKBB phenotype and biomarker information and correlated these with the deletions and duplications.

Results

We identified 11 individuals with large deletions relating to HNF1B and 106 with duplications. There were no significant difference in the average ages of deletion (53), duplication (56) and UKBB population (57). Of the 11, 3 were reported to have glomerular disease, 1 had haematuria, 1 had a renal transplant, and 6 had diabetes (55% vs. 5% amongst the rest of UKBB; P=2x10-6). The penetrance of diabetes was 30% and average eGFR was 71 (45% with eGFR<60) compared to average GFR 91(p<0.0001) in UKBB population. Their liver function is comparatively different. Gamma GT 110 v 37.4 (p<0.0001) and ALP 186.5 v 83.5 (p<0.0001) in UKBB population.

Average eGFR was lower in people with a duplication (80 v 91 in UKBB population, p<0.0001). We found no association between HNF1B duplication and diabetes (4.4% vs. 5.3%; P=0.8) or liver function.

Conclusion

HNF1B deletions and duplications can be detected in a large unselected dataset. Deletions are more pathogenic than duplications. However, HHF1B duplications do appear to affect renal function, which has not been previously described. The frequency of both HNF1B deletions and duplications may be higher than previously estimated.